Integrin-linked kinase (ILK) is a highly conserved serinethreonine protein kinase involved in cell-extracellular matrix interactions, cytoskeletal organization and cell signaling. Overexpression of ILK in epithelial cells leads to anchorage-independent growth with increased cell cycle progression. Previously, we have shown that ILK upregulation strongly correlates with melanoma progression, invasion and inversely correlates with 5-year survival of melanoma patients. However, the molecular mechanism by which ILK enhances melanoma progression is currently unknown. In the present study, we found that proangiogenic molecule interleukin-6 (IL-6) is the downstream target of ILK in melanoma cells. ILK overexpression increased IL-6, whereas silencing of ILK suppressed IL-6 expression at both messenger RNA and protein levels. ILK also altered the activity and subcellular localization of nuclear factor-kappaB (NF-jB) subunit p65. We further found that ILK enhanced the IL-6 gene transcription by promoting the binding of NF-kB p65 to IL-6 promoter. Moreover, ILK overexpression in melanoma cells enhanced the tube-forming ability of endothelial cells in vitro and microvessel formation in vivo. ILK-induced tube and blood vessel formation of endothelial cells was significantly reduced upon IL-6 inhibition in ILK-overexpressing melanoma cells. To delineate the mechanism by which ILK-induced IL-6 production can enhance angiogenesis, further analysis of the downstream targets of IL-6 signaling showed an increased activity of the signal transducer and activator of transcription 3 (STAT3) in ILK-overexpressing cells. As STAT3 binds to vascular endothelial growth factor (VEGF) promoter, we found that VEGF levels were elevated in ILK-overexpressing cells and declined upon transfection of IL-6 small interfering RNA, suggesting that ILK may regulate VEGF expression through IL-6 pathway by activating STAT3.
Introduction
Cutaneous melanoma is a malignant tumor of the skin that arises from abnormal proliferation of epidermal melanocytes (Houghton and Polsky, 2002) . It is one of the rarer types of skin cancer but accounts for 80% of the deaths associated with skin cancer (Jerant et al., 2000) . The incidence of malignant melanoma is increasing faster than the rate for any other neoplasm, except for lung cancer in women (Ries et al., 2000) . Despite many years of intensive laboratory and clinical research, treatment of the disease is arduous because of its stubborn resistance to conventional cancer therapies, such as radiation and chemotherapy (Soengas and Lowe, 2003) . Melanoma is highly invasive and prone to metastasis. Angiogenesis is a hallmark of melanoma progression (Czubayko et al., 1996; Dutcher, 2001 ). As angiogenesis is an essential feature of melanoma biology, the factors driving this process need to be understood for further therapeutic exploitation.
Integrin-linked kinase (ILK) is a component of the PI-3K pathway located upstream of protein kinase B (Hannigan et al., 1996; Wu and Dedhar, 2001; Troussard et al., 2003) . ILK interacts with cytoplasmic domain of b-integrin subunits and is activated by integrin activation as well as by growth factors (Wu and Dedhar, 2001) . It functions as an adapter protein in the multiprotein complexes that connect b1-integrins to the actin cytoskeleton and to intracellular signaling pathways (Hannigan et al., 1996) . Activated ILK can directly phosphorylate protein kinase B and glycogen synthase kinase-3. Phosphorylation of protein kinase B by ILK contributes to its activation, leading to suppression of apoptosis and anoikis (Wu and Dedhar, 2001) . Phosphorylation of glycogen synthase kinase-3 results in its inhibition, leading to stabilization of b-catenin and stimulation of the activator protein 1 (AP-1) activity. b-Catenin and cAMP response elementbinding (CREB) activation via ILK and glycogen synthase kinase-3 contribute to the upregulation of cyclin D1, whereas AP-1 activation leads to stimulation of matrix metalloproteinase-9 expression (Delcommenne et al., 1998; Lynch et al., 1999; Persad et al., 2000 Persad et al., , 2001 ; Wu and Dedhar, 2001; Troussard et al., 2003) . ILK also promotes cell migration and invasion (Persad and Dedhar, 2003) . Overexpression of ILK induces anchorage-independent cell growth, suppresses anoikis and promotes hyperplasia and tumor formation in vivo (Wu and Dedhar, 2001) . Overexpression or constitutive activation of ILK has been documented in several epithelial cancer types including melanoma (Graff et al., 2001; Ahmed et al., 2003; Bravou et al., 2003; Dai et al., 2003; Ito et al., 2003) . The expression of ILK-associated serine/threonine phosphatase (ILKAP), a negative regulator of ILK activity, is reduced in melanoma cells compared with normal melanocytes (Hoek et al., 2004) . Angiogenesis is driven by the tumor's release of vascular endothelial growth factor (VEGF), which binds to the receptors on endothelial cells of nearby blood vessels causing the endothelial cells to proliferate and bud from the existing blood vessel, and migrate toward the source of proangiogenic signal. ILK regulates hypoxia-inducible factor 1 alpha subunit (HIF-1a)-mediated VEGF expression in glioblastoma and prostate cancer cells, and is essential for VEGFstimulated endothelial cell migration, tube formation and tumor angiogenesis (Tan et al., 2004; Koul et al., 2005; Watanabe et al., 2005) .
Previously, we reported that ILK upregulation strongly correlates with melanoma progression, invasion, and inversely correlates with 5-year survival of melanoma patients (Dai et al., 2003) . We also found that ILK knockdown impeded melanoma cell migration and invasion in vitro, and significantly impaired the growth of melanoma xenografts in severe combined immunodeficient mice, indicating that ILK is critically important for melanoma tumor growth (Wong et al., 2007) . However, the molecular mechanism of ILKmediated melanoma growth is still not well understood and one of the factors responsible for this could be its involvement in angiogenesis of melanoma tumors.
Interleukin-6 (IL-6) is a pleiotropic cytokine and has both proinflammatory and anti-inflammatory functions. IL-6 has a wide range of biological functions, such as cell proliferation, differentiation, survival, apoptosis and angiogenesis. Recently, it has been demonstrated that the expression of IL-6 in tumor tissues is closely associated with the development of cancer. However, the influence of IL-6 in human cancers may vary, probably depending on the type of cancer (Wei et al., 2003) . In the present study, we showed that ILK promotes melanoma angiogenesis by upregulating IL-6 that induces VEGF expression via the signal transducer and activator of transcription 3 (STAT3) pathway.
Results

ILK regulates the expression of IL-6 and VEGF in melanoma cells
We used two melanoma cell lines, MMRU and SK-mel-3, to study the effect of increased ILK on IL-6 and VEGF expression. These two cells lines have moderate levels of endogenous ILK and secrete considerable amounts of IL-6 (Supplementary Figure S1) . The stable cells established by pcDNA3.1-vector or pcDNA3.1-ILK plasmid transfection were designated as MMRUvector and MMRU-ILK cell lines. Previously, we have also established stable ILK-knockdown MMRU cells by transfecting ILK-short hairpin RNA (shRNA) or control shRNA sequences (Wong et al., 2007) . In case of SK-mel-3 cells, we performed transient transfections to overexpress ILK using either empty or ILK-cDNA vector. The ILK protein was silenced in these cells by small interfering RNA (siRNA), and the experiments were performed with ILK-siRNA or control siRNA expressing SK-mel-3 cells. The overexpression and silencing of ILK protein in both MMRU and SKmel-3 cells was confirmed by western blot analysis ( Figure 1a) .
We found that overexpression of ILK in MMRU and SK-mel-3 cells significantly increased IL-6 messenger RNA (mRNA) and protein expression (Figures 1b and c) . These cells also exhibited significantly increased VEGF mRNA and protein levels (Figures 1a and b) . These results indicate that overexpression of ILK induces IL-6 and VEGF expression in melanoma cells. Conversely, to determine the effect of decreased ILK expression on IL-6 and VEGF, we used ILK-shRNA expressing stable MMRU cells, and found that IL-6 and VEGF mRNA and protein expression is drastically reduced in ILKshRNA compared with control shRNA cells (Figure 1) . Similarly, ILK-siRNA transfection into SK-mel-3 cells significantly inhibited IL-6 mRNA and protein expression (Figures 1b and c) . The ILK-siRNA cell transfection also resulted in significantly decreased VEGF mRNA and protein expression in SK-mel-3 cells (Figures 1a and 1b) . These results indicate that blockade of ILK expression suppressed IL-6 and VEGF expression in melanoma cells.
Involvement of nuclear factor-kappaB in ILK-induced IL-6 expression Nuclear factor-kappaB (NF-kB) activation has been reported to be necessary for induction of IL-6 (Libermann and Baltimore, 1990; Matsui et al., 1999) , and ILK is also known to regulate other genes through NF-kB (Tan et al., 2002) . Based on this evidence, we examined the status of NF-kB in melanoma cells. In both MMRU and SK-mel-3 cells, ILK overexpression resulted in increased NF-kB p65 serine-536 phosphorylation levels (Figure 2a ). NF-kB phosphorylation has a key role in the regulation of its transcriptional activity and DNA-binding activity (Chen and Greene, 2004) . Moreover, IkB kinases are known to phosphorylate NF-kB p65 on serine-536 in the transactivation domain (Sakurai et al., 1999) . Hence, we further examined the status of IkB protein in our system. We found a significant increase in IkBa phosphorylation in ILKoverexpressing cells compared with vector controls (Figure 2a) . We also observed stabilization of IkBa upon ILK knockdown that was consistent with the loss of phosphorylated IkBa in both MMRU and SK-mel-3 cells (Figure 2a ). To further investigate the role of NFkB in mediating the effects of ILK on IL-6 production, we used siRNA to knock down NF-kB p65 expression in vector and ILK-overexpressing MMRU cells. Silencing of NF-kB led to a significant reduction of IL-6 production ( Figure 2b ) and IL-6 transcript levels ( Figure 2c ). We achieved a 90% reduction of NF-kB p65 upon siRNA transfection (Figure 2d ). Taken together, these results suggest that ILK-induced upregulation of IL-6 in melanoma cells is dependent upon NF-kB.
ILK regulates IL-6 gene transcription by enhancing the nuclear translocation of NF-kB and its binding to IL-6 promoter To study the effects of ILK on the transcriptional activation of IL-6 gene, the activity of IL-6 promoter and NF-kB reporter was evaluated using dual-luciferase reporter assay (Delrieu et al., 1999) . Vector and ILKoverexpressing MMRU cells were transfected with an IL-6 promoter luciferase (p1178hu.IL6-luc þ ) and NF-kB luciferase reporter construct (3 Â -kB.luc þ ). The results demonstrate that ILK-overexpressing cells exhibited a 2.6-fold increase (Po0.01) in IL-6 promoter activity and 2.1-fold increase in NF-kB reporter activity (Po0.01) when compared with respective controls and normalized with Renilla activity (Figure 3a) .
To understand the effect of ILK expression upon protein levels of NF-kB, cytoplasmic and nuclear extracts of MMRU-vector, MMRU-ILK, control shRNA and ILK-shRNA cells were subjected to western analysis using NF-kB p65 antibody. Nuclear NF-kB p65 protein levels were significantly increased in ILK-overexpressing cells and reduced in ILK-knockdown cells compared with respective controls (Figure 3b , left panel). On the other hand, the cytoplasmic levels of NF-kB p65 were decreased in ILK-overexpressing cells and increased in ILK-knockdown cells (Figure 3b , right panel). However, no significant changes in NFkBp105/p50 subunit expression were observed in nuclear or cytoplasmic preparations from MMRUvector, MMRU-ILK, control shRNA and ILK-shRNA cells (data not shown). These results indicate that ILK induces nuclear translocation of NF-kB p65 in melanoma cells.
ILK indirectly regulates the expression of many proteins by activating transcription factor NF-kB and AP-1 (Troussard et al., 1999; D'Amico et al., 2000; Tan et al., 2002) . IL-6 promoter has a consensus binding sequence for NF-kB (Hershko et al., 2002) . To determine whether ILK expression affects the binding status of NF-kB to IL-6 promoter, electromobility shift assay (EMSA) was performed using nuclear extracts from MMRU cells transiently transfected with vector or ILK, stable control shRNA or shILK cells. Incubation of NF-kB p65 probe with nuclear extracts of ILKoverexpressing cells showed an induction of DNAbinding activity compared with the vector control ( Figure 3c , left panel, lanes 2 and 3). In contrast, the binding activity was drastically reduced in ILK-knockdown cells compared with control shRNA cells ( Figure 3c , left panel, lanes 4 and 5). Competition studies with the excess unlabeled NF-kB p65 motif probe completely prevented enhancement of the ILKinduced band ( Figure 3c , right panel). To further confirm the EMSA results, we tested the binding of NF-kB to the IL-6 gene promoter in vivo using chromatin immunoprecipitation assay. Increased binding of p65 to the consensus sequence of the IL-6 promoter was clearly detected upon ILK overexpression in MMRU cells (Figure 3d ), indicating that ILK is enhancing the binding of p65 to the IL-6 promoter sequence in vivo and helps in activating IL-6 gene transcription in melanoma cells.
ILK expression in melanoma cells induces IL-6-dependent angiogenic potential of endothelial cells in vitro
To provide evidence whether ILK regulates the angiogenic phenotype of melanoma cells via IL-6, we determined the angiogenic ability of vector and ILKoverexpressing MMRU cells using an endothelial cell tube formation assay. We found that the conditioned medium (CM) from ILK-overexpressing cells had greater angiogenic potential (number of tubes/field formed on matrigel) than the CM from vector cultures (Figure 4a ). However, when CM collected from vector or ILK-overexpressing cells that were simultaneously knocked down for IL-6 or its downstream target STAT3 was applied to human umbilical vein endothelial cells (HUVECs), the tube-forming network was drastically reduced (Figures 4a and b) . IL-6 siRNA transfection of MMRU-vector and MMRU-ILK cells led to an 85% reduction in IL-6 protein levels (Figure 4c ).
To further confirm the role IL-6 in ILK-induced in vitro angiogenesis, blockage of IL-6 in the CM from vector or ILK-overexpressing MMRU cells using IL-6 antibody resulted in reduced tube formation activity by HUVECs on the matrigel (Figure 4d ). Unconditioned medium containing growth factors, VEGF and basic fibroblast growth factor (bFGF), used as positive control also stimulated HUVEC growth on matrigel (Supplementary Figure S2a) . These findings suggest that ILK-induced IL-6 production has a critical role in vitro angiogenesis.
Targeting IL-6 in melanoma cells inhibits ILK-induced angiogenesis in vivo We next evaluated whether ILK expression in melanoma cells could promote the IL-6-dependent new blood vessel formation in vivo. To clarify the biological function of IL-6 in ILK-mediated angiogenesis, we blocked the function of IL-6 by siRNA in vector and ILK-overexpressing MMRU cells, and subsequently implanting the cells into nude mice as matrigel plugs. Visual examination of the excised matrigel plugs revealed varying levels of vascularization, with very few blood vessels observed in plugs from IL-6 siRNAtransfected cells compared with control siRNA-transfected vector or ILK-overexpressing cells (Figure 5a ). CD31 staining revealed that the control siRNA-treated vector or ILK-overexpressing plugs contained denser and more extensive microvessel networks. On the other hand, IL-6 siRNA-treated vector or ILK-overexpressing plugs exhibited a scanty pattern of endothelial structures, indicative of less extensive angiogenesis supporting these implants (Figures 5b and c) . Direct knockdown of ILK caused a reduction of endothelial cell growth and blood vessel formation (Supplementary Figure S2b) . This data confirmed that ILK may increase angiogenic activity in human melanoma cells in vivo via IL-6.
ILK induces IL-6-dependent STAT3 activation and VEGF expression in melanoma cells To further understand the mechanism by which ILKmediated IL-6 production enhances endothelial capillary tube formation, we explored the status of STAT3 in MMRU and SK-mel-3 cells. We found that ILK Figure 3 Effect of ILK upon IL-6 gene transcription and subcellular localization of NF-kB p65 and its binding to IL-6 promoter. (a) IL-6 promoter and NF-kB luciferase reporter activities of MMRU-vector and MMRU-ILK cells transfected with IL-6 promoter/ luciferase and NF-kB reporter plasmids. Whole-cell extracts were prepared 24 h after transfection, and luciferase levels were measured by luminometry. All values are expressed as mean ± s.d. The experiments were performed three times and similar results were obtained. **Po0.01. (b) ILK affects the nuclear localization of NF-kB p65. Nuclear and cytoplasmic extracts from MMRU cells expressing vector, wild-type ILK, control shRNA or ILK-shRNA were subjected to western blot analysis using NF-kB p65 antibody. Lamp2 was used as input control for cytosolic extracts, whereas histone H4 was used for nuclear extracts. (c) ILK enhances the binding of NF-kB p65 to IL-6 promoter. EMSA was performed using nuclear protein extracts from MMRU cells transiently transfected with vector or ILK, stable control shRNA or ILK-shRNA cells, and the oligonucleotide probes of putative NF-kB p65-binding region of the IL-6 promoter. A major shifted band was observed. Competition studies with the excess (100-and 500-fold) unlabeled NF-kB motif probe prevented the binding of ILK to IL-6 promoter (right panel). (d) Endogenous NF-kB p65 protein binding to the IL-6 gene promoter consensus sequence is enhanced in vivo upon ILK overexpression in MMRU cells as demonstrated by chromatin immunoprecipitation assay. **Po0.01. overexpression increased STAT3 tyrosine-705 phosphorylation in both MMRU cells and SK-mel-3 cells (Figure 6a ). siRNA-mediated targeting of IL-6 in vector or ILK-overexpressing cells inhibited the levels of phosphorylated STAT3 (Figure 6a) . Because IL-6 is reported to upregulate VEGF to induce angiogenesis (Wei et al., 2003; Huang et al., 2004; Loeffler et al., 2005; Adachi et al., 2006) , we used VEGF antibody to assay for differences in VEGF protein levels between the vector and ILK-overexpressing MMRU, and SK-mel-3 cells knocked down for IL-6 and STAT3 proteins. Control siRNA-transfected ILK-overexpressing melanoma cells exhibited a 1.4-to 1.5-fold increase in VEGF protein compared with the vector cells (Figure 6a) . Conversely, knockdown of either IL-6 or STAT3 expression in vector or ILK-overexpressing cells suppressed VEGF protein levels (Figure 6a ). These findings suggest that ILK may regulate VEGF expression via IL-6 in melanoma cells to induce melanoma angiogenesis. IL-6 protein levels were significantly reduced in both MMRU and SK-mel-3 cells upon IL-6 siRNA transfection (Figure 6b ), whereas transfection of STAT3 siRNA did not cause any significant changes in IL-6 production ( Figure 6b ).
Discussion
Several studies have indicated the importance of ILK in the oncogenesis of several malignancies including melanomas (Graff et al., 2001; Wu and Dedhar, 2001; Ahmed et al., 2003; Bravou et al., 2003; Dai et al., 2003; Ito et al., 2003; Persad and Dedhar, 2003) . Previously, we have shown that ILK expression increases as melanoma progresses. In addition, strong ILK expression also correlated with lymph node invasion and inversely related to 5-year patient survival (Dai et al., 2003) . We also reported that ILK knockdown impeded melanoma cell migration and invasion in vitro (Wong et al., 2007) . Moreover, ILK knockdown significantly impaired the growth of melanoma xenografts in severe combined immunodeficient mice, indicating that ILK is critically important for melanoma tumor growth (Wong et al., 2007) .
However, it is not clear how ILK regulates melanoma tumor growth and which other factors or molecules are involved. In this study, we sought to determine the molecular mechanism by which ILK promotes melanoma angiogenesis. We have previously reported that NF-kB p50 subunit promotes melanoma angiogenesis by upregulating IL-6 (Karst et al., 2009) . Hence, we first examined whether IL-6 levels are changed when ILK expression is altered in melanoma cells. ILK overexpression resulted in elevation of IL-6 and VEGF, whereas depletion of ILK protein caused a decline in IL-6 and VEGF expression. Furthermore, ILK expression caused an increase in NF-kB p65 Ser-536 phosphorylation, and inhibition of NF-kB p65 in vector or ILKoverexpressing cells resulted in reduction of IL-6 protein and mRNA levels (Figures 2b and c) . These data suggest that ILK has a crucial role in IL-6 expression via activation of NF-kB pathway in melanoma cells.
To further determine which transcription factor is transducing ILK signal, we assessed the effect of ILK on the expression of NF-kB. As ILK has been shown to regulate the activity of NF-kB in intestinal epithelial cells (Tan et al., 2002) , it is possible that ILK could regulate IL-6 expression via NF-kB in melanoma cells. In addition, NF-kB family has been shown to have a key role in cancer pathogenesis and is a promising target for therapy. Furthermore, we have previously reported that increased NF-kB p50 expression significantly correlates with melanoma progression and poor patient prognosis (Gao et al., 2006) . As it has been shown that RelA (p65) and p50 are the forms highly expressed in human metastatic melanoma, we determined the effect of ILK on the expression of NF-kB. Our results showed that ILK induces the nuclear expression of NF-kB p65, which correlated with a reduction of cytosolic expression, suggesting that ILK induced the cytosolnuclear translocation of NF-kB p65 (Figure 3b) . The increased activity and nuclear translocation of NF-kB could be because of increased IkBa phosphorylation in ILK-overexpressing cells and IkBa stabilization in ILK-knockdown cells, with the loss of IkBa phosphorylation (Figure 2a) . In our system, ILK seemed to regulate IL-6 expression by promoting the binding of NF-kB p65 to the IL-6 promoter as shown by both EMSA and chromatin immunoprecipitation studies (Figures 3c and  d) . Our data presented here support a significant role of NF-kB in ILK-mediated upregulation of IL-6 expression.
Although previous studies have confirmed that IL-6 is important in both physiological and pathological angiogenesis (Cohen et al., 1996; Mahnke et al., 2000) , IL-6 has recently received more attention as a critical cytokine implicated in the angiogenesis of several human cancers, including cervical cancer, basal cell carcinoma, glioma, gastric carcinoma and mesothelioma (Wei et al., 2003; Huang et al., 2004; Jee et al., 2004; Loeffler et al., 2005; Adachi et al., 2006; Saidi et al., 2009) . Strikingly, these investigations provide evidence that IL-6 may promote VEGF-induced tumor angiogenesis. In melanoma patients, serum IL-6 levels were significantly elevated with either localized or metastatic melanoma compared with controls. The higher IL-6 levels were significantly correlated with tumor progression and resistance to chemotherapy (Mouawad et al., 2002) .
As IL-6 is a secreted proangiogenic factor (LazarMolnar et al., 2000), we next examined whether inhibition of IL-6 in melanoma cells could impact ILK-induced endothelial cell tube formation in vitro. Our results confirmed that CM from ILK-overexpressing MMRU cells enhanced HUVEC tube formation on matrigel, and inhibition of IL-6 in vector or ILKoverexpressing MMRU cells to certain extent abolished this tube network. Interestingly, knockdown of IL-6 in vector or ILK-overexpressing MMRU cells in vivo resulted in reduced blood vessel formation that was confirmed by CD31 staining (Figure 5 ). These results strongly sugesst that IL-6 has a crucial role in ILKinduced angiogenesis in vitro and in vivo.
IL-6 is known to regulate VEGF through STAT3 pathway in many cancers and thereby promotes angiogenesis (Wei et al., 2003; Huang et al., 2004; Jee et al., 2004; Saidi et al., 2009) . We further examined whether silencing of IL-6 or its downstream target STAT3 in vector or ILK-overexpressing cells could affect VEGF expression. We found a significant decrease in VEGF protein in ILK-overexpressing cells knocked down for IL-6 or its downstream target STAT3, suggessting that ILK may activate STAT3 through enhanced IL-6 production and thereby induces VEGF expression, as activated STAT3 is known to bind to VEGF promoter (Niu et al., 2002) .
We have shown here for the first time that ILK overexpression can induce IL-6-mediated VEGF expression in melanoma cells and promote the tube network formation by endothelial cells in vitro. Moreover, we have demonstrated that ILK overexpression by melanoma cells enhances the formation of supportive vasculature in vivo, whereas knockdown of IL-6 inhibits the ILK-induced microvessel formation. Our work highlights a novel mechanism of melanoma angiogenesis, which is of critical importance, as neovascularization is one of the most important steps in the multistage progression of this aggressive malignancy. The ability of melanoma tissue to express high levels of IL-6 not only provides autocrine and paracrine growth stimulation (Lazar-Molnar et al., 2000) but may also induce angiogenesis, thus conferring an important survival advantage and metastatic potential to tumor cells.
In summary, the results of our study for the first time indicate that ILK strongly promotes melanoma angiogenesis and that it mediates this effect through activation of NF-kB p65 and upregulation of the proangiogenic cytokine IL-6. Based on this study, we propose that targeting the ILK/IL-6/STAT3 pathway may be an effective antiangiogenic therapeutic strategy for melanoma.
Materials and methods
Cell lines and culture conditions
The human melanoma cell lines MMRU (gift from Dr R Byers, Boston University) and SK-mel-3 (gift from Dr AP Albino, Memorial Sloan-Kettering Cancer, New York) were maintained in Dulbecco's Modified Eagle's Medium (Invitrogen, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (HyClone, South Logan, UT, USA). HUVECs were cultured in endothelial cell medium 2 (PromoCell, Heidelberg, Germany). All cells were maintained in an atmosphere of 5% CO 2 at 37 1C.
Transient or stable transfection of melanoma cells
Transient and stable transfections were performed using Effectene reagent (Qiagen, Mississauga, ON, Canada). To overexpress wild-type ILK, we transfected MMRU cells with 1 mg of pcDNA3.1-ILK or control vector pcDNA3.1 plasmids, kindly provided by Dr Showkat Dedhar (University of British Columbia, Canada). Stably transfected cell lines were isolated by selection with neomycin (G418). To inhibit ILK expression, MMRU cells were transfected with the ILK-shRNA expression vector or control shRNA vector, and stably transfected cells were isolated by G418 selection as described earlier (Wong et al., 2007) . SK-mel-3 cells were transiently transfected with pCDNA3.1-vector or pcDNA3.1-ILK plasmids to overexpress ILK. siRNAs At 50-60% confluency, MMRU or SK-mel-3 cells were transfected with siRNAs against ILK, NF-kB p65, IL-6 and STAT3 (ID numbers SI00288176, SI102663094, SI00012579 and SI02662338, Qiagen) using SiLentFect reagent (Bio-Rad, Mississauga, ON, Canada) according to the manufacturer's instructions.
Western blot and enzyme-linked immunosorbent assay Protein extracts for western blot were prepared using hypotonic buffer (10 mM HEPES (pH 8.0), 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM EDTA 0.5 mM DTT) containing a protease inhibitor cocktail (Roche Diagnostics, Laval, QC, Canada). Protein concentration was quantified by Bio-Rad protein assay dye reagent (Bio-Rad), and western blot was performed as previously described (Karst et al., 2009) . The following antibodies were used in this study: anti-ILK, anti-p-Ser32 IkB, anti-IkB, anti-p-Ser536-p65 and anti-p-Tyr705 STAT3 (Cell signaling Technology, Boston, MA, USA), anti-p105/ p50, anti-p65, anti-lamp2, anti-histone H4, anti-STAT3 and anti-VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and monoclonal mouse anti-actin (Sigma-Aldrich, St Louis, MO, USA). Signals were detected using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA). For enzyme-linked immunosorbent assay, a human IL-6 ELISA kit from eBioscience (San Diego, CA, USA) was used according to the manufacturer's instructions.
Real-time reverse transcription PCR
We performed real-time reverse transcription PCR analysis of the IL-6 and VEGF genes, and we used b-actin as an internal control. Total RNA was isolated with TRIzol reagent (Invitrogen). First-strand complementary DNA was synthesized from 3 mg of total RNA using SuperScript First-Strand Synthesis System (Invitrogen) according to the manufacturer's protocol. We performed reverse transcription PCR using 2 ml of complementary DNA and the SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) as recommended by the manufacturer. The sequence of primers for IL-6 and VEGF are: IL-6 primers, 5 0 -ATACCTAGAGTACCTCCA GAACAG-3 0 (forward) and 5 0 -TGGCATTTGTGGTTG GGTCA-3 0 (reverse); VEGF primers, 5 0 -GCGGAGAAAGCA TTTGTTTGT-3 0 (forward) and 5 0 -CGGCTTGTCACATCT GCAA-3 0 (reverse). Each sample was run in triplicate for the target gene and the internal control gene.
Luciferase reporter assays
Two different luciferase plasmids were used in these assays. The full-size human IL-6 promoter reporter gene construct (p1178hu.IL6-luc þ ) was kindly provised by Dr Masaaki Murakami (Osaka University, Japan). The NF-kB luciferase reporter plasmid (3 Â kB.luc þ ) was a kind gift from Dr Albert S Baldwin (University of North Carolina, USA). MMRU cells were plated in equal number in triplicate in 24-well plates and transfected with IL-6 promoter or 3 Â kB reporter plasmids. Luciferase activities in the lysates were determined after 24 h using the Dual-Luciferase Reporter assay system (Promega, Madison, WI, USA). Luciferase levels were normalized by Renilla pRL-CMV plasmid transfection.
EMSAs
For nuclear extracts, cells were grown to confluency, and nuclear extracts were prepared using NXtract kit (SigmaAldrich). EMSA was performed as previously described (Xiao et al., 2004) . Briefly, 15 mg of protein was incubated with binding buffer containing 1 mg poly (dI:dC) (Sigma) in a total volume of 25 ml for 15 min before the addition of 32 P-labeled probe. Similarly, for competition assays, the unlabeled oligonucleotides were added to reaction mixtures for 15 min at room temperature before addition of labeled probe. The binding complexes were separated on 5% polyacrylamide gel. The gel was dried and exposed to X-ray film for the detection of complexes. The wild-type NF-kB oligonucleotide sequences used as either probe or competitor for EMSA are as follows: 5 0 -CAAATGTGGGATTTTCCCATGAGTC-3 0 (sense); 5 0 -G ACTCATGGGAAAATCCCACATTTG-3 0 (antisense).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was performed as described previously (Karst et al., 2009) . Briefly, MMRU cells were transfected with pCDNA3.1-vector or pCDNA3.1-ILK plasmids. After 24 h, formaldehyde-fixed cells were immunoprecipitated overnight with rabbit anti-NF-kBp65 antibody (Abcam, Cambridge, MA, USA), and the associated genomic DNA was analyzed by quantitative PCR. The sequence of PCR primers spanning the NF-kB p65-binding site on the IL-6 promoter region are as follows: forward primer (5 0 -CCCTCACCCTCCAACAAAG-3 0 ) and reverse primer (5 0 -TTGTGGAGAAGGAGTTCATAGC-3 0 ). The corresponding PCR product of 187 bp was amplified.
Endothelial tube formation assay
The endothelial tube formation assay was performed as previously described with minor modifications (Maeshima et al., 2000) . MMRU cells were cultured in complete medium. After 24 h, the CM was collected, and either added directly to HUVECs for HUVEC tube formation assays or stored at À80 1C for IL-6 protein quantification by enzyme-linked immunosorbent assay. Matrigel (BD Biosciences, Mississauga, ON, Canada) was coated on 96-well tissue culture plates and allowed to polymerize. HUVECs were harvested, and at least 10 4 cells were seeded onto each well. Endothelial cell tube formation was examined after 16 h. The cells were photographed using inverted phase contrast microscope, and tube formation was quantified by counting the number of connected cells in randomly selected fields under Â 10 magnification.
In vivo angiogenesis and CD31 staining In vivo angiogenesis assay and immunofluorescent staining of CD31 were performed as described previously (Karst et al., 2009) . MMRU cells stably expressing vector or ILK protein were transiently transfected with control siRNA or IL-6 siRNA for 48 h. Four groups of cells (MMRU-vector/control siRNA, MMRU-vector/IL-6 siRNA, MMRU-ILK/control siRNA and MMRU-ILK/IL-6 siRNA) were suspended in 100 ml phosphate buffered saline, mixed with 0.5 ml matrigel and implanted subcutaneously into the flanks of 6-week-old male nude mice. The animals were sacrificed after 10 days whereupon the matrigel plugs were photographed and stained with anti-mouse CD31 antibody (Santa Cruz Biotechnology). Fluorescent signals were visualized using a Zeiss fluorescent microscope (Carl Zeiss, Toronto, ON, Canada) equipped with a 12-bit Retiga Ex digital camera (Leeds Precision Instruments, Minneapolis, MN, USA) and Northern Eclipse imaging software (Northern Eclipse, Santa Clara, CA, USA). 4 0 ,6-diamidino-2-phenylindole (DAPI) nuclear staining indicated the overall cell density of each matrigel plug.
Statistical analysis
Student's t-test was used to perform statistical analyses. Data is presented as average±s.d. A P-value o0.05 was considered significant.
